GET DAILY SIGNALSCaris Life Sciences (CAI) Reports Strong Q3 Revenue Growth and Raises Full-Year Guidance
Key Takeaways
- Total revenue reached $275.4 million in Q3 2026, up 27% year over year and ahead of consensus estimates.
- GAAP (Generally Accepted Accounting Principles) earnings per share (EPS) came in at $0.05, beating analyst expectations.
- Net income declined to $15.3 million from $24.3 million a year earlier as operating expenses rose 42%.
- Gross margin slipped to 66% from 68%, reflecting higher costs even as the top line accelerated.
- Management raised full-year 2026 revenue guidance to $1.04 billion to $1.05 billion, implying 28% to 29% growth.
- Molecular profiling services drove the quarter with $262.7 million in revenue, up 27% year over year.
- For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated analysis pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention in the market.
Why the Quarter Matters
Caris Life Sciences (CAI) operates as a precision-medicine and artificial-intelligence TechBio company that applies molecular profiling to guide cancer treatment decisions and support drug development. The third-quarter results provide a useful checkpoint on whether the company can sustain its revenue momentum while controlling the higher expenses that come with scaling operations. Recent periods have shown consistent top-line beats, yet profitability has faced pressure from increased spending on research, marketing, and personnel. From what I see, this report helps investors gauge demand for molecular diagnostics, the path of margins, and whether the updated guidance points to lasting strength in a competitive oncology-testing space.
The Quarter in Detail
CAI posted total revenue of $275.4 million for the third quarter of 2026, marking a 27% rise from $216.8 million in the prior-year period and exceeding the consensus estimate of approximately $255 million. Revenue from molecular profiling services increased 27% to $262.7 million, while pharma research and development services added $12.7 million, compared with $9.2 million a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GAAP net income totaled $15.3 million, or $0.05 per share on both a basic and diluted basis, surpassing the consensus EPS estimate of $0.03 to $0.04. Gross profit climbed to $182.3 million, yet the gross margin narrowed to 66% from 68%. Operating expenses rose 42% to $163.0 million, which contributed to a drop in income from operations to $19.3 million from $32.6 million and adjusted EBITDA of $44.4 million versus $51.2 million a year earlier.
Management lifted its full-year 2026 revenue outlook to a range of $1.04 billion to $1.05 billion, equating to 28% to 29% growth, and reiterated expectations for roughly 20% growth in clinical therapy selection volume.
Market Reaction and Investor Views
Heading into the release, sentiment leaned cautiously optimistic, with expectations for a year-over-year EPS decline even as revenue continued to advance. The beats on both revenue and EPS provided a positive surprise, though the margin contraction and lower net income introduce a note of caution. Investors will likely balance the evident demand for molecular profiling against the costs required to support that growth. Because the company reports after the market close, the complete post-earnings price move will hinge on how the market interprets the raised guidance alongside the margin trends and the quarter’s negative free cash flow of $39.7 million.
What to Watch Going Forward
After the Q3 2026 report, the key question for CAI centers on whether revenue growth can eventually support better profitability. The raised full-year revenue guidance reflects management confidence in demand, yet investors should monitor whether gross margins stabilize as the business expands.
Discipline around operating expenses will remain important. Higher outlays for headcount, research and development, and marketing weighed on operating income even as sales grew. Signs that these investments are beginning to produce higher-margin, recurring revenue would be constructive.
Clinical volume growth also merits attention, with management anticipating an approximate 20% increase for the year. Continued rises in molecular profiling cases, together with progress in pharma research and development services, will help determine whether CAI can carry its top-line momentum into fiscal 2027.
Free cash flow turned negative this quarter after being positive a year earlier. Tracking cash-flow trends, any further guidance updates, and competitive conditions in oncology diagnostics will matter for evaluating the company’s route to sustainable profitability.
Using Tickeron’s AI Tools in My Research
In my own analysis, I regularly turn to Tickeron’s AI Screener to quickly filter stocks by fundamentals, technical patterns, and AI-driven signals. It helps surface relevant comparisons during earnings season without the need for manual screening, which keeps the process efficient when evaluating names like CAI alongside peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAI's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CAI turned positive on October 21, 2026. Looking at past instances where CAI's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CAI as a result. In 24 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +7.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 46 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 5 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 15 of 17 cases where CAI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CAI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.688) is normal, around the industry mean (3.051). P/E Ratio (3.429) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (125.677) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of leasing international intermodal marine cargo containers
Industry Biotechnology
Advertisement